Join
Live feed
·
PRReleasevia Quantisnow
BridgeBio Oncology Therapeutics Inc. logo

BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

ByQuantisnow·Wall Street's wire, on your screen.
BBOT· BridgeBio Oncology Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBOT (BridgeBio Oncology Therapeutics Inc.) and more on Quantisnow.